Wall Street Zen Downgrades Repligen (NASDAQ:RGEN) to Hold

Repligen (NASDAQ:RGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.

A number of other brokerages have also recently commented on RGEN. Jefferies Financial Group decreased their price target on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, September 12th. Evercore ISI raised their target price on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Finally, Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $169.62.

Repligen Stock Up 1.3%

Shares of RGEN opened at $154.54 on Friday. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52. The firm’s 50 day moving average is $129.66 and its 200-day moving average is $126.62. The stock has a market capitalization of $8.69 billion, a PE ratio of -618.14, a P/E/G ratio of 2.82 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts forecast that Repligen will post 1.72 EPS for the current year.

Insider Activity

In related news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Delta Investment Management LLC acquired a new position in shares of Repligen during the third quarter worth $6,779,000. CWM LLC increased its holdings in shares of Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after buying an additional 135 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Repligen by 305.4% during the third quarter. Pacer Advisors Inc. now owns 10,213 shares of the biotechnology company’s stock valued at $1,365,000 after acquiring an additional 7,694 shares during the last quarter. Norden Group LLC bought a new position in shares of Repligen during the third quarter valued at $317,000. Finally, Trust Co. of Vermont bought a new position in shares of Repligen during the third quarter valued at $67,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.